Chronic Leukemias

Chronic Leukemias

A collection of features and news articles published in ASH Clinical News related to chronic leukemias.

You Make the Call

How would you treat a patient with CLL who developed warm autoimmune hemolytic anemia?

This month, Dr. Jacobsen discusses how to treat a patient with chronic lymphocytic leukemia who develops warm autoimmune hemolytic anemia. And don't forget to check...
On location

Adding Venetoclax to Obinutuzumab Prolongs Progression-Free Survival in Previously Untreated CLL

In a phase III trial of patients with previously untreated chronic lymphocytic leukemia (CLL) and co-existing comorbidities, a fixed-duration regimen of obinutuzumab plus venetoclax...
On location

Single-Agent Ibrutinib Improves Survival and Prolongs Time to Next Treatment in Early-Stage CLL

In the double-blind, randomized CLL12 trial, patients with treatment-naïve, early-stage chronic lymphocytic leukemia (CLL) who received single-agent ibrutinib had longer event-free survival (EFS), progression-free...

Ibrutinib Plus Venetoclax Leads to High Rates of MRD Negativity in Frontline CLL

The combination of ibrutinib with venetoclax – two agents that have been approved for the treatment of chronic lymphocytic leukemia (CLL) – led to...

TKIs Linked to Increased Cardiovascular and Arteriothrombotic Events in Chronic-Phase CML

In patients with chronic-phase chronic myeloid leukemia (CML), treatment with tyrosine kinase inhibitors (TKIs) has been shown to increase the risk of cardiovascular and...
On location

Can Women With CML Safely Continue TKIs During Pregnancy?

Most women with chronic myeloid leukemia (CML) who received treatment with tyrosine kinase inhibitors (TKIs) and became pregnant had a normal childbirth, with no...
On location

Single-Agent Acalabrutinib Improves Survival in Relapsed/Refractory Chronic Lymphocytic Leukemia

According to results from the phase III ASCEND trial, treatment with acalabrutinib as a single agent improved progression-free survival (PFS) compared with idelalisib or...

Robert Kreitman: Delayed Versus Concurrent Rituximab in Hairy Cell Leukemia

Robert Kreitman, MD, shares results from a new study suggesting patients with hairy cell leukemia should receive rituximab concurrently with frontline cladribine.
On location

Flumatinib Superior to Imatinib in Chronic-Phase Chronic Myeloid Leukemia

Flumatinib, a second-generation tyrosine kinase inhibitor (TKI), led to more molecular responses that were also deeper, compared with imatinib, in patients with newly diagnosed...
On location

Should Patients With Hairy Cell Leukemia Receive Delayed or Concurrent Rituximab?

For more than 30 years, the standard firstline treatment of hairy cell leukemia (HCL) has been single-agent purine analog therapy, usually cladribine, but a...
Advertisement

Current Issue

September 2019 Volume 5 Issue 11

September 2019, Volume 5, Issue 11

This issue explores politics in the exam room, demystifies proteomic analysis in hematology, and more.